Interaction of Rio1 kinase with toyocamycin reveals a conformational switch that controls oligomeric state and catalytic activity

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Kiburu, Irene N ^a   LaRonde LeBlanc, Nicole ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; OLIGOMER; PHOSPHOTRANSFERASE; RIO1 KINASE; TOYOCAMYCIN; UNCLASSIFIED DRUG;

ARCHAEOGLOBUS FULGIDUS; ARTICLE; AUTOPHOSPHORYLATION; CATALYSIS; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE; MONOMERIZATION; NONHUMAN; OLIGOMERIZATION; PROTEIN INTERACTION; REGULATORY MECHANISM; RIBOSOME; STEADY STATE; X RAY;

ARCHAEOGLOBUS FULGIDUS; HUMANS; LIGANDS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN-SERINE-THREONINE KINASES; TOYOCAMYCIN;

ARCHAEA; ARCHAEOGLOBUS FULGIDUS;

EID: 84861302592     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037371     Document Type: Article

References (54)

1. Akoulitchev S, Chuikov S, Reinberg D, (2000) TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature 407: 102-105.
2. Connell-Crowley L, Solomon JM, Wei N, Harper WJ, (1992) Phosphorylation Independent Activation of Human Cyclin-Dependent Kinase2 by CyclinA InVitro. Mol Biol Cell 4: 79-92.
3. Fromont-Racine M, Senger B, Saveanu C, Fasiolo F, (2003) Ribosome assembly in eukaryotes. Gene 313: 17-42.
4. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S, (2002) The Protein Kinase Complement of the Human Genome. Science 298: 1912-1934.
5. LaRonde-LeBlanc N, Wlodawer A, (2005) A family portrait of the Rio Kinases. J Biol Chem 280: 37297-37300.
6. LaRonde-LeBlanc N, Wlodawer A, (2004) Crystal Structure of A. fulgidus Rio2 Defines a New Family of Serine Protein Kinases. Structure 12: 1585-1594.
7. Hanks SK, Quinn AM, Hunter T, (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241: 42-52.
8. Angermayr M, Bandlow W, (2002) RIO1, an extraordinary novel protein kinase. FEBS letters 524: 31-36.
9. LaRonde-LeBlanc N, Copeland T, Wlodawer A, (2005) Autophosphorylation of Archaeoglobus fulgidus Rio2 and crystal structures of its nucleotide-metal ion complexes. FEBS Journal 272: 2800-2810.
10. Humbard MA, Reuter CJ, Zuobi-Hasona K, Zhou G, Maupin-Furlow JA, (2010) Phosphorylation and Methylation of Proteasomal Proteins of the Haloarcheon Haloferax volcanii. Archaea 2010 1-10 pp. 1-10.
11. Vanrobays E, Gleizes PE, Bousquet-Antonelli C, Noaillac-Depeyre J, Caizergues-Ferrer M, et al. (2001) Processing of 20S pre-rRNA to 18S ribosomal RNA in yeast requires Rrp10p, an essential non-ribosomal cytoplasmic protein. The EMBO Journal 20: 4204-4213.
12. Vanrobays E, Gelugne JP, Gleizes PE, Caizergues-Ferrer M, (2003) Late Cytoplasmic Maturation of the Small Ribosomal Subunit Requires RIO Proteins in Saccharomyces cerevisiae. Mol Cell Biol 23: 2083-2095.
13. Angermayr M, Roldl A, Bandlow W, (2002) Yeast Rio1p is the founding member of a novel subfamily of protein serine kinases involved in the control of cell cycle progression. Mol Microbiol 44: 309-324.
14. Venema J, Tollervey D, (1999) Ribosome Synthesis in Saccharomyces cerevisae. Annu Rev Genet 33: 216-311.
15. Ben-Sham A, Jenner L, Yusupova G, Yusupov M, (2010) Crystal Structure of the Eukaryotic Ribosome. Science 330: 1203-1208.
16. Pardee AB, (1989) G1 events and regulation of cell proliferation. Science 246: 603-608.
17. Pyronnet S, Sonenberg N, (2001) Cell-cycle-dependent translational control. Curr Opin Genet Dev 11: 11-18.
18. Derenzini M, Trere D, Pession A, Govoni M, Sirri V, et al. (2000) Nucleolar size indicates the rapidity of cell proliferation in cancer tissues. J Pathol 191: 181-186.
19. Tavitian A, Uretsky CS, George A, (1968) Selective inhibition of ribosomal RNA synthesis in mammalian cells. Biochim Biophys Acta 157: 33-42.
20. Heine U, (1969) Electron Microscopic Studies on HeLa Cells Exposed to the Antibiotic Toyocamycin. Cancer Research 29: 1875-1880.
21. Riman J, Sverak L, Langlois AJ, Bonar RA, Beard JW, (1969) Influence of Toyocamycin on RNA Synthesis in Chick Embryo Cells Noninfected and Infected with Strain MC29 Avian Leukosis Virus'. Cancer Research 29: 1707-1716.
22. Cohen BM, Glazer IR, (1984) Cytotoxicity and the Inhibition of Ribosomal RNA Processing in Human Colon Carcinoma cells. Mol Pharmacol 27: 308-313.
23. Nishioka H, Sawa T, Hamada M, Shimura N, Imoto M, et al. (1990) Inhibition of Phosphatidylinositol Kinase by Toyocamycin. J Antibiot 12: 1586-1589.
24. Long MC, Parker WB, (2006) Structure-activity relationship for nucleoside analogs as inhibitors or substrates of adenosine kinase from Mycobacterium tuberculosis. Biochem Pharmacol 71: 1671-1682.
25. Palczewski K, Kahn N, Hargrave PA, (1990) Nucleoside Inhibitors of Rhodopsin Kinase. Biochemistry 29: 6276-6282.
26. LaRonde-LeBlanc N, Guszczynski T, Copeland T, Wlodawer A, (2005) Structure and activity of the atypical serine kinase Rio1. FEBS Journal 272: 3698-3713.
27. Otwinowski Z, Minor W, (1997) Processing of X-ray Diffraction Data Collected in Oscillation Mode. Method Enzymol 276: Macromolecular Crystallography, part A 307-326.
28. Vagin A, Teplyakov A, (2000) An approach to multi-copy search in molecular replacement. Acta Crystallogr D Biol Crystallogr 56: 1622-1624.
29. Potterton E, Briggs P, Turkenburg M, Dodson E, (2003) A graphical user interface to the CCP4 program suite. Acta Crystallogr D Biol Crystallogr 59: 1131-1137.
30. Vagin A, Teplyakov A, (2010) Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr 66: 22-25.
31. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
32. Murshudov GN, Vagin AA, Dodson EJ, (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255.
33. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, et al. (2002) PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58: 1948-1954.
34. Adams PD, Gopal K, Grosse-Kunstleve RW, Hung LW, Ioerger TR, et al. (2004) Recent developments in the PHENIX software for automated crystallographic structure determination. J Synchrotron Radiat 11: 53-55.
35. Johnson ML, Correia JJ, Yphantis DA, Halvorson HR, (1981) Analysis of data from the analytical ultracentrifuge by nonlinear least-squares techniques. Biophys J 36: 575-588.
36. Krissinel E, Henrick K, (2007) Inference of macromolecular assemblies from crystalline state. J Mol Biol 372: 774-797.
37. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J, (2006) An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor. Cell 125: 1137-1149.
38. Reed MC, Lieb A, Nijhout F, (2010) The biological significance of substrate inhibition: A mechanism with diverse functions. Bioessays 32: 422-429.
39. Mansour TE, (1972) Phosphofructokinase activity in skeletal muscle extracts following administration of epinepherine. J Biol Chem 19: 6059-6066.
40. Uyeda K, Furuya E, Lub LJ, (1981) The effect of natural and synthetic D-fructose 2,6-bisphosphate on the regulatory kinetic properties of liver and muscle phosphofructokinases. J Biol Chem 256: 8394-8399.
41. Su JY, Storey KB, (1994) Regulation of rainbow trout white muscle phosphofructokinase during exercise. Int J Biochem 26: 519-528.
42. Hayouka Z, Rosenbluh J, Levin A, Loya S, Lebendiker M, et al. (2007) Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Pro Natl Acad Sci USA 104: 8316-8321.
43. Jaffe E, Lawrence SH, (2012) The Morpheein Model of Allostery: Evaluating Proteins as Potential Morpheeins. Method Mol Biol 796: 217-231.
44. Jaffe E, (2005) Morpheeins - a new structural paradigm for allosteric regulation. Trends Biochem Sci 30: 490-497.
45. Kokona B, Rigotti DJ, Wasson AS, Lawrence SH, Jaffe EK, et al. (2008) Probing the Oligomeric Assemblies of Pea Porphobilinogen Synthase by Analytical Ultracentrifugation. Biochemistry 47: 10649-10656.
46. Selwood T, Tang L, Lawrence SH, Anokhina Y, Jaffe EK, (2008) Kinetics and Thermodynamics of the Interchange of the Morpheein Forms of Human Porphobilinogen Synthase. Biochemistry 47: 3245-3257.
47. Angermayr M, Hochleitner E, Lottspeich F, Bandlow W, (2007) Protein kinase CK2 activates the atypical Rio1p kinase and promotes its cell-cycle phase-dependent degradation in yeast. FEBS Journal 274: 4654-4667.
48. Widmann B, Wandrey F, Badertscher L, Wyler E, Pfannstiel J, et al. (2012) The kinase activity of human Rio1 is required for final steps of cytoplasmic maturation of 40S subunits. Mol Biol Cell 23: 22-35.
49. Guderian G, Peter C, Wiesner J, Sickmann A, Schulze-Osthoff K, et al. (2011) RioK1, a New Interactor of Protein Arginine Methyltransferase 5 (PRMT5), Competes with pICln for Binding and Modulates PRMT5 Complex Composition and Substrate Specificity. J Biol Chem 286: 1976-1985.
50. Witte O, (2005) Unraveling Kinase Signalling Pathways with Chemical Genetic and Chemical Proteomic Approaches. Cell Cycle 4: 434-437.
51. Bishop AC, Buzko O, Shokat KM, (2001) Magic bullets for protein kinases. Trends Cell Biol 11: 167-172.
52. Shah K, Liu Y, Deirmengian C, Shokat KM, (1997) Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Pro Natl Acad Sci USA 94: 3565-3570.
53. Stockwell BR, (2000) Chemical Genetics: Ligand-based discovery of gene function. Nat Rev Genet 11: 116-125.
54. Gyenis L, Duncan JS, Turowec JP, Bretner M, Litchfield DW, (2011) Unbiased Functional Proteomics Strategy for Protein Kinase Inhibitor Validation and Identification of bona fide Protein Kinase Substrates: Application to Identification of EEF1D as a Substrate for CK2. J Proteome Res10: 4887-4901.